gtbiopharma.com - שינוי בהכנסות משנה לשנה ב-12 החודשים האחרונים GTBP

Speculative interest in leukemia therapy amid high risks drives the current valuation of GT Biopharma, Inc. (GTBP). This chart of annual sales growth over the TTM demonstrates volatility, where the current parameter equals 0.00. GT Biopharma, Inc. (GTBP) is implementing immune activation methods to combat metastases and developing strategic partnerships with pharma behemoths to accelerate the commercialization of its innovative medical developments.
פילוחי נתונים אנליטיים מרוכזים עבור GT Biopharma Corporation (GTBP)

For GT Biopharma, Inc. (GTBP), which implements robotic screening of TriKE-conjugates to accelerate preclinical stages, this indicator serves as a measure of the commercial efficiency of its innovations. By analyzing current revenue dynamics over a 12-month period compared to the same period, an investor can see the percentage change in sales volume on a TTM basis, allowing for a real-time assessment of cash flow resilience to macroeconomic shocks between quarterly reports.